MiNK Therapeutics, Inc.INKTNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P41
Within normal range
vs 3Y Ago
-3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -2.50% |
| Q2 2025 | 51.56% |
| Q1 2025 | 61.57% |
| Q4 2024 | -31.38% |
| Q3 2024 | 8.23% |
| Q2 2024 | -17.11% |
| Q1 2024 | -42.56% |
| Q4 2023 | 22.53% |
| Q3 2023 | 0.56% |
| Q2 2023 | 7.32% |
| Q1 2023 | -20.80% |
| Q4 2022 | 12.71% |
| Q3 2022 | 0.84% |
| Q2 2022 | -13.33% |
| Q1 2022 | -11.47% |
| Q4 2021 | 194.26% |
| Q3 2021 | -8.45% |
| Q2 2021 | 49.95% |
| Q1 2021 | 87.66% |
| Q4 2020 | -33.94% |
| Q3 2020 | -17.31% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |